Henkie Isahwan Ahmad Mulyadi Lai

Dr. Henkie Isahwan Ahmad Mulyadi Lai

Universiti Selangor
orcid

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
Verified
Journal Article
Open access
PDF file
WCWei Chiu
Wei Chiu
TLTing Yi Lin
Ting Yi Lin
YCYun chia Chang
Yun chia Chang
Henkie Isahwan Ahmad Mulyadi LaiHenkie Isahwan Ahmad Mulyadi Lai
Henkie Isahwan Ahmad Mulyadi Lai
SLShen-Che Lin
Shen-Che Lin
DHDe-Kuang Hwang
De-Kuang Hwang
Inherited retinal dystrophies (IRDs) are a group of rare eye diseases caused by gene mutations that result in the degradation of cone and rod photoreceptors or the retinal pigment epithelium. Retinal degradation progress is often irreversible, with clinical manifestations including color or night blindness, peripheral visual defects and subsequent vision loss. Thus, gene therapies that restore functional retinal proteins by either replenishing unmutated genes or truncating mutated genes are needed. Coincidentally, the eye’s accessibility and immune-privileged status along with major advances in gene identification and gene delivery systems heralded gene therapies for IRDs. Among these clinical trials, voretigene neparvovec-rzyl (Luxturna), an adeno-associated virus vector-based gene therapy drug, was approved by the FDA for treating patients with confirmed biallelic RPE65 mutation-associated Leber Congenital Amaurosis (LCA) in 2017. This review includes current IRD gene therapy clinical trials and further summarizes preclinical studies and therapeutic strategies for LCA, including adeno-associated virus-based gene augmentation therapy, 11-cis-retinal replacement, RNA-based antisense oligonucleotide therapy and CRISPR-Cas9 gene-editing therapy. Understanding the gene therapy development for LCA may accelerate and predict the potential hurdles of future therapeutics translation. It may also serve as the template for the research and development of treatment for other IRDs.

23 October 2020 in Science Advances
Verified
Journal Article
Open access
PDF file
PYPeng Yang
Peng Yang
SCShih-Jie Chou
Shih-Jie Chou
JLJindian Li
Jindian Li
WHWenqiao Hui
Wenqiao Hui
WLWenfei Liu
Wenfei Liu
HTHsian-Rong Tseng
Hsian-Rong Tseng
CRISPR-Cas9 knockin of the HBB gene paves the way for a general therapeutic solution for treating hemoglobinopathies.

Verified
Journal Article
Open access
PDF file
Henkie Isahwan Ahmad Mulyadi LaiHenkie Isahwan Ahmad Mulyadi Lai
Henkie Isahwan Ahmad Mulyadi Lai
SCShih-Jie Chou
Shih-Jie Chou
YCYueh Chien
Yueh Chien
PTPing-Hsing Tsai
Ping-Hsing Tsai
CCChianshiu Chien
Chianshiu Chien
YYYi-Ping Yang
Yi-Ping Yang
Angiotensin-converting enzyme 2 (ACE2) was identified as the main host cell receptor for the entry of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and its subsequent infection. In some coronavirus disease 2019 (COVID-19) patients, it has been reported that the nervous tissues and the eyes were also affected. However, evidence supporting that the retina is a target tissue for SARS-CoV-2 infection is still lacking. This present study aimed to investigate whether ACE2 expression plays a role in human retinal neurons during SARS-CoV-2 infection. Human induced pluripotent stem cell (hiPSC)-derived retinal organoids and monolayer cultures derived from dissociated retinal organoids were generated. To validate the potential entry of SARS-CoV-2 infection in the retina, we showed that hiPSC-derived retinal organoids and monolayer cultures endogenously express ACE2 and transmembrane serine protease 2 (TMPRSS2) on the mRNA level. Immunofluorescence staining confirmed the protein expression of ACE2 and TMPRSS2 in retinal organoids and monolayer cultures. Furthermore, using the SARS-CoV-2 pseudovirus spike protein with GFP expression system, we found that retinal organoids and monolayer cultures can potentially be infected by the SARS-CoV-2 pseudovirus. Collectively, our findings highlighted the potential of iPSC-derived retinal organoids as the models for ACE2 receptor-based SARS-CoV-2 infection.

12 January 2022 in Biomedicines
Verified
Journal Article
Open access
PDF file
HTHao-Yu Tsai
Hao-Yu Tsai
Henkie Isahwan Ahmad Mulyadi LaiHenkie Isahwan Ahmad Mulyadi Lai
Henkie Isahwan Ahmad Mulyadi Lai
ZCZhang-Yuan Chen
Zhang-Yuan Chen
TLTai-Chi Lin
Tai-Chi Lin
WKWinnie Khor
Winnie Khor
SCShih-Jie Chou
Shih-Jie Chou
Autophagy plays a protective role in the retinal pigment epithelium (RPE) by eliminating damaged organelles in response to reactive oxygen species (ROS). Dual-specificity protein phosphatase 6 (DUSP6), which belongs to the DUSP subfamily, works as a negative-feedback regulator of the extracellular signal-regulated kinase (ERK) pathway. However, the complex interplay between DUSP6 and autophagy induced by ROS in RPE is yet to be investigated. To investigate the relationship between DUSP6 and autophagy, we exposed the ARPE-19 cell line and C57BL/6N mice to sodium iodate (NaIO3) as an oxidative stress inducer. Our data showed that the inhibition of DUSP6 activity promotes autophagy flux through the ERK pathway via the upregulation of immunoblotting expression in ARPE-19 cells. Live imaging showed a significant increase in autophagic flux activities, which suggested the restoration autophagy after treatment with the DUSP6 inhibitor. Furthermore, the mouse RPE layer exhibited an irregular structure and abnormal deposits following NaIO3 injection. The retina layer was recovered after being treated with DUSP6 inhibitor; this suggests that DUSP6 inhibitor can rescue retinal damage by restoring the mouse retina’s autophagy flux. This study suggests that the upregulation of DUSP6 can cause autophagy flux malfunctions in the RPE. The DUSP6 inhibitor can restore autophagy induction, which may serve as a potential therapeutic approach for retinal degeneration disease.

4 August 2021 in Frontiers in Cell and Developmental Biology
Verified
Journal Article
Open access
CCChian-Shiu Chien
Chian-Shiu Chien
YCYueh Chien
Yueh Chien
YLYi-Ying Lin
Yi-Ying Lin
PTPing-Hsing Tsai
Ping-Hsing Tsai
SCShih-Jie Chou
Shih-Jie Chou
CWChien-Ying Wang
Chien-Ying Wang
Non-viral gene delivery holds promises for treating inherited diseases. However, the limited cloning capacity of plasmids may hinder the co-delivery of distinct genes to the transfected cells. Previously, the conjugation of maleimide-functionalized polyurethane grafted with small molecular weight polyethylenimine (PU-PEI600-Mal) using 1,6-hexanedithiol (HDT) could promote the co-delivery and extensive co-expression of two different plasmids in target cells. Herein, we designed HDT-conjugated PU-PEI600-Mal for the simultaneous delivery of CRISPR/Cas9 components to achieve efficient gene correction in the induced pluripotent stem cell (iPSC)-derived model of Fabry cardiomyopathy (FC) harboring GLA IVS4 + 919 G > A mutation. This FC in vitro model recapitulated several clinical FC features, including cardiomyocyte hypertrophy and lysosomal globotriaosylceramide (Gb3) deposition. As evidenced by the expression of two reporter genes, GFP and mCherry, the addition of HDT conjugated two distinct PU-PEI600-Mal/DNA complexes and promoted the co-delivery of sgRNA/Cas9 and homology-directed repair DNA template into target cells to achieve an effective gene correction of IVS4 + 919 G > A mutation. PU-PEI600-Mal/DNA with or without HDT-mediated conjugation consistently showed neither the cytotoxicity nor an adverse effect on cardiac induction of transfected FC-iPSCs. After the gene correction and cardiac induction, disease features, including cardiomyocyte hypertrophy, the mis-regulated gene expressions, and Gb3 deposition, were remarkably rescued in the FC-iPSC-differentiated cardiomyocytes. Collectively, HDT-conjugated PU-PEI600-Mal-mediated dual DNA transfection system can be an ideal approach to improve the concurrent transfection of non-viral-based gene editing system in inherited diseases with specific mutations.

12 November 2026 in Organoids
Verified
Journal Article
Open access
PDF file
Henkie Isahwan Ahmad Mulyadi LaiHenkie Isahwan Ahmad Mulyadi Lai
Henkie Isahwan Ahmad Mulyadi Lai
RIRickie Isahdie
Rickie Isahdie
SVSuci Ventasamia
Suci Ventasamia
SPSukrit Promtang
Sukrit Promtang
Natural products offer diverse chemical structures and pharmacological activities for therapeutic discovery. Their translation benefits from evidence that connects a reproducible preparation with relevant exposure and a clearly defined biological response. Organoids can strengthen this evidence by providing tissue architecture, cellular diversity, and donor-specific features suited to focused experimental questions. This critical narrative review uses a structured literature search to synthesize representative natural-product studies across tumor, intestinal, hepatic, renal, pulmonary, cortical, retinal, and cardiac platforms. Direct organoid evidence, findings from related three-dimensional models, and prospective applications are distinguished by material, species, derivation, exposure, and endpoint. The selected examples illustrate these distinctions rather than provide a comprehensive evidence map. We propose an exposure-aware conceptual decision framework linking material identity, assay compatibility, exposure plausibility, model fitness, functional activity, and context-specific validation. Six gates guide advance, iterate, or stop/redirect decisions and make the evidence supporting each claim explicit. The framework provides a practical structure for study design and reporting, with prospective evaluation as the next step. Roselle serves as an illustrative botanical example for future organoid testing. Used alongside analytical studies, two-dimensional cultures, animal models, and clinical research, qualified organoids can help move natural-product discovery toward reproducible, tissue-level, and decision-relevant evidence.